AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01501149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
Description: DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study NCT04335422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)
Description: Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
Study NCT04335422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (routine physical and rehabilitation medicine program)
Description: Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
Study NCT04335422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group (routine physical and rehabilitation medicine program)
Description: Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
Study NCT04387825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSVF application in the right hand
Description: 40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
Study NCT04385927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Net for Parents of Neurodiverse Children
Description: One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
Study NCT00745225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
Study NCT00745225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 1 capsule daily, 96 weeks.
Study NCT03431311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Therapy (ACT)
Description: T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
Study NCT00603967 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual x-ray absorptiometry (DXA)
Description: Baseline, 6 months, and 12 months
Study NCT00603967 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
Study NCT00603967 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline
Study NCT03095248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Continuous twice daily dosing; oral agent
Study NCT03334734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: Once a day for 14 days
Study NCT03334734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Once a day for 14 days
Study NCT01456949 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Arctic Front® Cardiac CryoAblation System
Description: Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
Study NCT03046550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTM-1634
Description: NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
Study NCT03365908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block
Description: An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
Study NCT03365908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 15 mL of 0.5% ropivacaine will be administered for the adductor canal block
Study NCT03874858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib oral 300 mg QD hard capsules
Study NCT03874858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib oral 300 mg BID hard capsules
Study NCT03874858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
Study NCT04403490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: 2 weeks HABIT-ILE
Study NCT04403490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: 2 weeks usual intervention (waitlist group)
Study NCT01653028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01653028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00803218 — intervention group
Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of one day
Study NCT00803218 — intervention group
Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Test product
Description: Small amount applied and evaluated over the course of one day
Study NCT01911637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VBY-036
Description: Study drug VBY-036
Study NCT01911637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-036
Description: Study drug VBY-036
Study NCT01911637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01911637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01943708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPAP
Description: Novel Auto-algorithm for Auto-CPAP device
Study NCT01943708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Standard CPAP therapy
Study NCT02590302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Phase
Description: Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site.
Study NCT01732731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: Home-based treadmill training will be administered to the children in the experimental group
Study NCT00847119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
Study NCT00847119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda)
Description: Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
Study NCT00847119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rectal Radiotherapy
Description: Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
Study NCT00107926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licarbazepine
Study NCT00107926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01496768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7,2 g/day during 3 months
Study NCT01496768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: 7,2 g/day during 3 months
Study NCT01165190 — intervention group
Intervention type: OTHER
Intervention: pioglitazone
Study NCT00930982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
Study NCT00930982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of matching placebo twice a day
Study NCT02272543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish surimi peptide
Study NCT02272543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish surimi peptide
Study NCT02557438 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Determination of the kind of surgery will be made by the participant's providers and not by study staff
Study NCT02557438 — intervention group
Intervention type: PROCEDURE
Intervention: Vertical Sleeve Gastrectomy
Description: Determination of the kind of surgery will be made by the participant's providers and not by study staff
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Tramadol Hydrochloride 20 mg i.v.
Study NCT04092283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01501149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
Description: MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study NCT00650429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
Study NCT04641546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
Study NCT04576481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
Study NCT04576481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
Study NCT04576481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret
Description: Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
Study NCT04576481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
Study NCT04624204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg Q3W
Study NCT04624204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg
Description: Pembrolizumab 400 mg Q6W
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab placebo (saline)
Description: Pembrolizumab placebo (saline) Q3W
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab placebo (saline)
Description: Pembrolizumab placebo (saline) Q6W
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg BID
Description: Olaparib 300 mg twice daily (BID)
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib matching placebo
Description: Olaparib matching placebo BID
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olaparib matching placebo
Description: Olaparib matching placebo BID
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
Study NCT04641546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupation-Based Intervention
Description: Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
Study NCT00105729 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive referral to 12-step self-help groups
Study NCT04929873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closed transdyser
Description: When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
Study NCT04929873 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine monitor
Description: Obtain oxygen saturation, skin color, temperature, etc
Study NCT04546256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04546256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 500/50
Description: 2 inhalations of Test and Reference product in each study period
Study NCT02046564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Study NCT02046564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04303585 — intervention group
Intervention type: PROCEDURE
Intervention: SAP block
Description: The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
Study NCT04303585 — intervention group
Intervention type: PROCEDURE
Intervention: ESP block
Description: The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide 100 mg/m^2
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum, investigator's choice
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
Study NCT04624204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum, investigator's choice
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
Study NCT04624204 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Thoracic Radiotherapy
Description: Standard Thoracic Radiotherapy
Study NCT04624204 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Thoracic Radiotherapy
Description: Standard Thoracic Radiotherapy
Study NCT04624204 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study NCT01481571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrification medium oocyte, warming medium oocyte and Rapid-i
Description: Media and device for vitrification of human oocytes
Study NCT04624204 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study NCT01744418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAVG graft implantation
Description: Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
Study NCT04652882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: oral capsule
Study NCT04652882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT03390673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD204
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
Study NCT03390673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
Study NCT02531100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BonyPid 500TM implantation concomitantly to SOC treatment
Description: BonyPid 500TM implantation concomitantly to SOC treatment
Study NCT02531100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC treatment only
Description: Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
Study NCT02531100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SOC treatment only
Description: Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
Study NCT02416310 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
Study NCT02416310 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
Study NCT02416310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
Study NCT03935399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: 10 IU oxytocin (Pitocin) for intramuscular injection